GE Healthcare is partnering with three organizations to improve cancer care: the University of Cambridge in the U.K., Optellum, and Sophia Genetics.
The three alliances are intended to help GE Healthcare support integrated health systems and medical professionals with diagnosis and treatment of cancer patients.
The University of Cambridge and Addenbrooke's Hospital plan to cooperate with GE on the development of an artificial intelligence (AI)-enhanced application that integrates cancer patient data from multiple sources into a single interface, according to a company statement.
GE and Optellum will help providers determine the malignancy of a lung nodule using AI. Optellum's Virtual Nodule Clinic identifies and scores the probability of malignancy, which may enable patients whose nodules are not malignant avoid unnecessary and aggressive procedures such as biopsy and surgical resection.
Sophia Genetics and GE will collaborate on various initiatives and projects, including advancing cancer care with the goal of better targeting and matching treatments to each patient's genomic profile and cancer type, helping to ensure the most effective and personalized treatment.
The two will initially work together on the creation of infrastructure to integrate data between GE's Edison platform and the Sophia DDM platform, as well as co-marketing and pilot site recruitment across oncology and radiogenomics.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
